Organically modified silica nanoparticles are biocompatible and can be targeted to neurons in vivo

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Barandeh, Farda ^a   Nguyen, Phuong Lan ^a   Kumar, Rajiv ^b   Iacobucci, Gary J ^a   Kuznicki, Michelle L ^a   Kosterman, Andrew ^a   Bergey, Earl J ^b   Prasad, Paras N ^b   Gunawardena, Shermali ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NANOPARTICLE; SILICON DIOXIDE; ORMOSIL; SILOXANE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; CELL NUCLEUS; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DROSOPHILA; IN VIVO STUDY; LARVAL DEVELOPMENT; LARVAL STAGE; NANOPROBE; NANOTECHNOLOGY; NERVE CELL; NERVE CELL NECROSIS; NERVE PROJECTION; NONHUMAN; PERIKARYON; SURVIVAL RATE; TARGET CELL; ANIMAL; ANIMAL EMBRYO; BLOOD BRAIN BARRIER; CELL CULTURE; CHEMISTRY; CYTOLOGY; DRUG DELIVERY SYSTEM; DRUG EFFECT; EVALUATION; FEMALE; GROWTH, DEVELOPMENT AND AGING; MALE; MATERIALS TESTING; METABOLISM; METHODOLOGY; PRENATAL DEVELOPMENT; PRIMARY CELL CULTURE;

ANIMALS; BLOOD-BRAIN BARRIER; CELLS, CULTURED; DROSOPHILA; DRUG DELIVERY SYSTEMS; EMBRYO, NONMAMMALIAN; FEMALE; MALE; MATERIALS TESTING; NANOPARTICLES; NEURONS; PRIMARY CELL CULTURE; SILICON DIOXIDE; SILOXANES;

EID: 84855301792     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029424     Document Type: Article

References (51)

1. Kim S, Lim YT, Soltesz EG, De Grand AM, Lee J, et al. (2004) Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat Biotechnol 22: 93.
2. Nyk M, Kumar R, Ohulchanskyy TY, Bergey EJ, Prasad PN, (2008) High contrast in vitro and in vivo photoluminescence bioimaging using near infrared to near infrared up-conversion in Tm3+ and Yb3+ doped fluoride nanophosphors. Nano Lett 8: 3834.
3. Deissler V, Ruger R, Frank W, Fahr A, Kaiser WA, et al. (2008) Fluorescent liposomes as contrast agents for in vivo optical imaging of edemas in mice. Small 4: 1240.
4. Ghoroghchian PP, Frail PR, Susumu K, Blessington D, Brannan AK, et al. (2005) Near-infrared-emissive polymersomes: self-assembled soft matter for in vivo optical imaging. Proc Natl Acad Sci USA 102: 2922.
5. Altinoglu EI, Russin TJ, Kaiser JM, Barth BM, Eklund PC, et al. (2008) Near-infrared emitting fluorophore-doped calcium phosphate nanoparticles for in vivo imaging of human breast cancer. ACS Nano 2: 2075.
6. Josephson L, Kircher MF, Mahmood U, Tang Y, Weissleder R, (2002) Near-infrared fluorescent nanoparticles as combined MR/optical imaging probes. Bioconjugate Chem 13: 554.
7. Park JH, von Maltzahn G, Ruoslahti E, Bhatia SN, Sailor MJ, (2008) Micellar hybrid nanoparticles for simultaneous magnetofluorescent imaging and drug delivery. Angew Chem Int Ed 47: 7284.
8. Kumar R, Roy I, Ohulchanskyy TY, Goswami LN, Bonoiu AC, et al. (2008) Covalently dye-linked, surface-controlled, and bioconjugated organically modified silica nanoparticles as targeted probes for optical imaging. ACS Nano 2: 449.
9. Slowing II, Wu CW, Vivero-Escoto JL, Lin VS, (2009) Mesoporous silica nanoparticles for reducing hemolytic activity towards mammalian red blood cells. Small 5: 57-62.
10. Ow H, Larson DR, Srivastava M, Baird BA, Webb WW, et al. (2005) Bright and stable core-shell fluorescent silica nanoparticles. Nano Lett 5: 113.
11. Zhao X, Hilliard LR, Mechery SJ, Wang Y, Bagwe RP, et al. (2004) A rapid bioassay for single bacterial cell quantitation using bioconjugated nanoparticles. Proc Natl Acad Sci USA 101: 15027.
12. Sharma RK, Das S, Maitra A, (2004) Surface modified ormosil nanoparticles. J Colloid Interface Sci 277: 342-6.
13. Qian J, Li X, Wei M, Gao X, Xu Z, et al. (2008) Bio-molecule-conjugated fluorescent organically modified silica nanoparticles as optical probes for cancer cell imaging. Opt Express 16: 19568-78.
14. Walcarius A, Ganesan V, (2006) Ion-exchange properties and electrochemical characterization of quaternary ammonium-functionalized silica microspheres obtained by the surfactant template route. Langmuir 22: 469-77.
15. Han L, Sakamoto Y, Che S, Terasaki O, (2009) Insight into the defects of cage-type silica mesoporous crystals with Fd3m symmetry: TEM observations and a new proposal of "polyhedron packing" for the crystals. Chemistry 15: 2818-25.
16. Santra S, Liesenfeld B, Dutta D, Chatel D, Batich CD, et al. (2005) Folate conjugated fluorescent silica nanoparticles for labeling neoplastic cells. J Nanosci Nanotechnol 5: 899-904.
17. Santra S, Yang H, Dutta D, Stanley JT, Holloway PH, et al. (2004) TAT conjugated, FITC doped silica nanoparticles for bioimaging applications. Chem Commun (Camb) 24: 2810-1.
18. Bharali DJ, Klejbor I, Stachowiak EK, Dutta P, Roy I, et al. (2005) Organically modified silica nanoparticles: a nonviral vector for in vivo gene delivery and expression in the brain. Proc Natl Acad Sci U S A 102: 11539-44.
19. Roy I, Ohulchanskyy TY, Pudavar HE, Bergey EJ, Oseroff AR, et al. (2003) Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy. J Am Chem Soc 125: 7860-5.
20. Kim S, Ohulchanskyy TY, Pudavar HE, Pandey RK, Prasad PN, (2007) Organically modified silica nanoparticles co-encapsulating photosensitizing drug and aggregation-enhanced two-photon absorbing fluorescent dye aggregates for two-photon photodynamic therapy. J Am Chem Soc 129: 2669-75.
21. Adams MD, Celniker SE, Holt RA, Evans CA, Gocayne JD, et al. (2000) The genome sequence of Drosophila melanogaster. Science 287: 2185-95.
22. Lessing D, Bonini NM, (2009) Maintaining the brain: insight into human neurodegeneration from Drosophila melanogaster mutants. Nat Rev Genet 10: 359-70.
23. Affleck JG, Walker VK, (2008) A role for Drosophila in understanding drug-induced cytotoxicity and teratogenesis. Cytotechnology 57: 1-9.
24. Nichols CD, (2006) Drosophila melanogaster neurobiology, neuropharmacology, and how the fly can inform central nervous system drug discovery. Pharmacol Ther 112: 677-700.
25. Rand MD, (2010) Drosophotoxicology: the growing potential for Drosophila in neurotoxicology. Neurotoxicol Teratol 32: 74-83.
26. Kumar R, Roy I, Ohulchanskky TY, Vathy LA, Bergey EJ, et al. (2010) In vivo biodistribution and clearance studies using multimodal organically modified silica nanoparticles. ACS Nano 4: 699-708.
27. Qu L, Akbergenova Y, Hu Y, Schikorski T, (2009) Evolutionary conservation of vertebrate blood-brain barrier chemoprotective mechanisms in Drosophila. J Comparative Neurology 514: 343-352.
28. de Jong G, van Dijk JP, van Eijk HG, (1990) The biology of transferrin. Clin Chim Acta 190: 1-46.
29. Qian ZM, Li AN, Sun H, Ho K, (2002) Targeted Drug Delivery via the Transferrin Receptor- Mediated Endocytosis Pathway. Pharmacol Rev 54: 561-587.
30. Gunawardena S, Goldstein LS, (2001) Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila. Neuron 32: 389-401.
31. Satpute-Krishnan P, Degiorgis JA, Conley MP, Jang M, Bearer EL, (2006) A peptide zipcode sufficient for anterograde transport within amyloid precursor protein. Proc Natl Acad Sci U S A 103: 16532-7.
32. Ashburner M, Thompson JN, (1978) The laboratory culture of Drosophila. In: Ashburner M, Wright TRF, editors. The Genetics and Biology of Drosophila, vol. 2a London Academic Press pp. 1-109.
33. Ashburner M, Golic KG, Hawley RS, (2005) Drosophila: a laboratory handbook. Second edition pp. xxviii + 1408.
34. Pavlidis P, Tanouye MA, (1995) Seizures and failures in the giant fiber pathway of Drosophila bang-sensitive paralytic mutants. J Neurosci 8: 5810-9.
35. Lee J, Wu CF, (2002) Electroconvulsive seizure behavior in Drosophila: analysis of the physiological repertoire underlying a stereotyped action pattern in bang-sensitive mutants. J Neurosci 22: 11065-79.
36. Fye S, Dolma K, Kang MJ, Gunawardena S, (2010) Visualization of larval segmental nerves in 3rd instar Drosophila larval preparations. J Vis Exp 43: 2128.
37. Hewes RS, Snowdeal EC 3rd, Saitoe M, Taghert PH, (1998) Functional redundancy of FMRFamide-related peptides at the Drosophila larval neuromuscular junction. J Neurosci 18: 7138-51.
38. Meeusen T, Mertens I, Clynen E, Baggerman G, Nichols R, et al. (2002) Identification in Drosophila melanogaster of the invertebrate G protein-coupled FMRFamide receptor. Proc Natl Acad Sci U S A 99: 15363-8.
39. Pereanu W, Spindler S, Im E, Buu N, Hartenstein V, (2007) The emergence of patterned movement during late embryogenesis of Drosophila. Dev Neurobiol 67: 1669-85.
40. Kuznicki ML, Gunawardena S, (2010) In vivo visualization of synaptic vesicles within Drosophila larval segmental axons. J Vis Exp 44: 2151.
41. Ohulchanskyy TY, Roy I, Goswami LN, Chen Y, Bergey EJ, et al. (2007) Organically modified silica nanoparticles with covalently incorporated photosensitizer for photodynamic therapy of cancer. Nano Lett 7: 2835-42.
42. Gunawardena S, Goldstein LS, (2005) Polyglutamine diseases and transport problems: deadly traffic jams on neuronal highways. Arch Neurol 62: 46-51.
43. Gunawardena S, Goldstein LS, (2004) Cargo-carrying motor vehicles on the neuronal highway: transport pathways and neurodegenerative disease. J Neurobiol 58: 258-71.
44. Gunawardena S, Her LS, Brusch RG, Laymon RA, Niesman IR, et al. (2003) Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 40: 25-40.
45. Hurd DD, Saxton WM, (1996) Kinesin mutations cause motor neuron disease phenotypes by disrupting fast axonal transport in Drosophila. Genetics 144: 1075-85.
46. Pluskota A, Horzowski E, Bossinger O, von Mikecz A, (2009) In Caenorhabditis elegans nanoparticle-bio-interactions become transparent: silica-nanoparticles induce reproductive senescence. PLoS One 4: e6622.
47. Kaspar BK, Lladó J, Sherkat N, Rothstein JD, Gage FH, (2003) Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301: 839-42.
48. Kells AP, Fong DM, Dragunow M, During MJ, Young D, et al. (2004) AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease. Mol Ther 9: 682-8.
49. Hsich G, Sena-Esteves M, Breakefield XO, (2002) Critical issues in gene therapy for neurologic disease. Hum Gene Ther 13: 579-604.
50. Mayer F, Mayer N, Chinn L, Pinsonneault RL, Kroetz D, et al. (2009) Evolutionary conservation of vertebrate blood-brain barrier chemoprotective mechanisms in Drosophila. J Neurosci 29: 3538-50.
51. Kraft R, Levine RB, Restifo LL, (1998) The steroid hormone 20-hydroxyecdysone enhances neurite growth of Drosophila mushroom body neurons isolated during metamorphosis. J Neurosci 18: 8886-99.